Registry Studies
Below you will find an overview of projects that use anonymized data from the MS Register.
Information on handling register data and applying to use it can be found here.
| Project title | Status | Approval | Publication |
|---|---|---|---|
| Einfluss unterschiedlicher MS-Therapeutika auf Inzidenz und Prognose von Myokardinfarkten: Eine Analyse basierend auf Patientendaten des MS-Registers | ongoing | November 2024 | - |
| Nicht-randomisierte Auswertung von Registerdaten zur Nutzenbewertung von Arzneimitteln (NANA) | ongoing | November 2024 | - |
| Zahlen, Daten und Fakten der MS in Baden-Württemberg - aktuelle Daten aus dem Deutschen MS-Register der DMSG | finished | January 2024 | - |
| An improved implementation of prediction intervals for overdispersed negative-binomially-distributed count data | finished | November 2023 | - |
| Analyse des Patientenguts mit einer late-onset multiple sclerosis anhand von Daten des deutschen Multiple Sklerose Registers auf der Basis ausgewählter Kriterien und statistischer Methoden zur Erfassung möglicher epidemiologischer, klinischer sowie diagnostischer Charakteristika. | ongoing | April 2023 | - |
| Potential hochwirksamer Arzneimitteltherapien zur Stärkung der beruflichen Teilhabe bei Multipler Sklerose | ongoing | November 2022 | - |
| Predicting disease activity and rebound risk in MS patients treated with sphingosine-1-phosphate receptor modulators | finished | October 2022 | - |
| Analyse des Therapiewechsels und der Therapieabfolgen bei deutschen RMS-Patienten Analysis of DMT switches and DMT sequencing in German multiple sclerosis patients |
finished | December 2021 | Article Therapeutic Advances in Neurological Disorders 2024 |
| Evaluation of the Effect of Physiotherapy on Disability Outcome Metrics in Multiple Sclerosis | ongoing | July 2021 | - |
| Age and Multiple Sclerosis - Persons with multiple sclerosis older than 55 | finished | June 2021 | Neurowoche 2022 Article Journal of Neurology 2024 |
| MS treatment profiles in Germany - insights from two major MS cohorts | finished | March 2021 | Poster ECTRIMS 2021 Poster ECTRIMS 2021 |
| A real-world evaluation of multifaceted aspects of progressive MS, including: 1. Patients’ characteristics and natural course of disease in the subjects treated and untreated with DMTs. 2. Clinical and demographic characteristics of the patients treated with siponimod in real world settings |
finished | February 2021 |
Poster AAN 2021 Abstract Neurology April 2021 Poster ABN 2021 Article Journal of Neurology, Neurosurgery & Psychiatry 2022 |
| Evaluating the population size and disease characteristics of Secondary Progressive Multiple Sclerosis patients in European Registries using different diagnostic criteria | finished | July 2021 |
Abstract Neurology April 2020 Presentation MS Virtual 2020 Presentations MS Virtual 2020 Layperson-Article aktiv! 2020 |
| DMSG Daten zu Epilepsie bei Multipler Sklerose in Deutschland | finished | January 2020 |
Article Multiple Sclerosis Journal October 2021 Article Therapeutic Advances in Neurological Disorders October 2023 |
| Generalisierbarkeit von klinischen Studien am Beispiel neuer Medikamente für MS Patienten | ongoing | January 2020 |
Article Mulitple Sclerosis Journal January 2021 Article Mulitple Sclerosis and Related Disorders January 2023 |
| Switch von Fingolimod zu Cladribine, Ocrelizumab oder Natalizumab | ongoing | - | Poster AAN 2021 Poster AAN 2021 Abstract Neurology April 2021 Abstract Neurology April 2021 |
| Characterization of early cladribine users among relapsing multiple sclerosis patients | finished | October 2019 | - |
| Aktive SPMS | finished | June 2019 | Article Multiple Sclerosis and Related Disorders September 2021 |